Resource Summary Report

Generated by NIF on Apr 19, 2025

Oncotator

RRID:SCR_005183

Type: Tool

Proper Citation

Oncotator (RRID:SCR_005183)

Resource Information

URL: http://www.broadinstitute.org/cancer/cga/oncotator

Proper Citation: Oncotator (RRID:SCR_005183)

Description: A tool for annotating human genomic point mutations and indels with data relevant to cancer researchers. Genomic Annotations, Protein Annotations, and Cancer Annotations are aggregated from many resources. A standalone version of Oncotator is being developed.

Abbreviations: Oncotator

Resource Type: data analysis service, production service resource, analysis service resource, service resource

Keywords: annotate, genomic, point mutation, indel, mutation, genome, protein, variant

Related Condition: Cancer

Funding:

Resource Name: Oncotator

Resource ID: SCR_005183

Alternate IDs: OMICS_00178

Record Creation Time: 20220129T080228+0000

Record Last Update: 20250419T055009+0000

Ratings and Alerts

No rating or validation information has been found for Oncotator.

No alerts have been found for Oncotator.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 202 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF.

Liu X, et al. (2024) Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma. Nature communications, 15(1), 3169.

Zhang J, et al. (2024) Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. Signal transduction and targeted therapy, 9(1), 65.

Díaz-Gay M, et al. (2024) The mutagenic forces shaping the genomic landscape of lung cancer in never smokers. medRxiv: the preprint server for health sciences.

Chang Y, et al. (2024) CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II. Briefings in bioinformatics, 26(1).

Choudhury AD, et al. (2024) Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. Cancer immunology research, 12(6), 704.

Zou H, et al. (2024) Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. Journal for immunotherapy of cancer, 12(3).

Czerniak B, et al. (2024) Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping. Research square.

Yang Z, et al. (2024) Genomic characteristics and immune landscape of super multiple primary lung cancer. EBioMedicine, 101, 105019.

Qian L, et al. (2024) Proteomic landscape of epithelial ovarian cancer. Nature communications, 15(1), 6462.

Ohara K, et al. (2024) The evolution of metastatic upper tract urothelial carcinoma through

genomic-transcriptomic and single-cell protein markers analysis. Nature communications, 15(1), 2009.

Fléchon L, et al. (2024) Genomic profiling of mycosis fungoides identifies patients at high risk of disease progression. Blood advances, 8(12), 3109.

Meuser E, et al. (2024) PIGA Mutations and Glycosylphosphatidylinositol Anchor Dysregulation in Polyposis-Associated Duodenal Tumorigenesis. Molecular cancer research: MCR, 22(6), 515.

Pan JW, et al. (2024) Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer. NPJ breast cancer, 10(1), 60.

Cheong TC, et al. (2024) Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancers. Nature communications, 15(1), 5110.

Walton J, et al. (2024) PRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma. Nature communications, 15(1), 8232.

Tarantino G, et al. (2024) Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma. Science advances, 10(48), eadp4670.

Chen J, et al. (2024) Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research, 30(11), 2571.

Nokin MJ, et al. (2024) RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nature communications, 15(1), 7554.

Darbandsari A, et al. (2024) Al-based histopathology image analysis reveals a distinct subset of endometrial cancers. Nature communications, 15(1), 4973.

Zhao X, et al. (2024) Clinicopathological characteristics and genomic profiling in patients with transformed lymphoma: a monocentric retrospective study. Annals of medicine, 56(1), 2419556.